Crossmark

Medication-overuse headache: a widely recognized entity amidst ongoing debate

Crossref DOI link: https://doi.org/10.1186/s10194-018-0875-x

Published Online: 2018-07-13

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vandenbussche, Nicolas http://orcid.org/0000-0001-8400-1163
Laterza, Domenico

Lisicki, Marco

Lloyd, Joseph

Lupi, Chiara

Tischler, Hannes

Toom, Kati

Vandervorst, Fenne

Quintana, Simone

Paemeleire, Koen

Katsarava, Zaza
License Information

Text and Data Mining valid from 2018-07-13
More Information

Article History

Received: 15 April 2018

Accepted: 13 June 2018

First Online: 13 July 2018

Authors’ information

: Nicolas Vandenbussche, Domenico Laterza, Marco Lisicki, Joseph Lloyd, Chiara Lupi, Hannes Tischler, Kati Toom, Fenne Vandervorst and Simone Quintana are Junior Fellows of EHF-SAS.Koen Paemeleire and Zaza Katsarava are Senior Fellows of EHF-SAS.

: Not applicable.

: Not applicable.

: NV has received travel and educational grants from Allergan.KP has received personal compensation from Allergan, Almirall, Amgen/Novartis, Autonomic Technologies Inc., Coherex, Janssen-Cilag, Lilly, Medtronic, Pfizer, Sandoz, Sanofi, St Jude Medical and Teva for consulting, serving on a scientific advisory board and/or speaking. ZK has received honoraria from Novartis, Allergan, MSD, Lilly, TEVA.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.